NCT03093116 2026-04-03TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 5 FDA
NCT07020221 2026-04-03A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsVerastem, Inc.Phase 1/2 Recruiting295 enrolled
NCT06445062 2026-04-01Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRevolution Medicines, Inc.Phase 1/2 Recruiting1,130 enrolled